OASIS: Single Jetrea injection results in long-term resolution of vitreomacular adhesion

Issue: December 25, 2015

LAS VEGAS — A single intravitreal injection of 0.125 mg of ocriplasmin can result in long-term resolution of vitreomacular adhesion, according to a presentation here.

At the American Academy of Ophthalmology annual meeting, Peter K. Kaiser, MD, presented results from the OASIS study evaluating a single injection of Jetrea (ocriplasmin, Thrombogenics) in patients with vitreomacular adhesion (VMA), including macular hole, and vitreomacular traction (VMT) at 24 months.

Peter K. Kaiser, MD

The rate of VMA/VMT resolution was 41.7% in the ocriplasmin group compared with 6.2% in the sham group at day 28 after injection (P < .001).

“If you look at the timing of this release, the majority of it occurred by day 28, which is important, because then you know if it didn’t work by day 28 to proceed with vitrectomy,” Kaiser said.

The presence of subretinal fluid at baseline predicted outcomes, with 51.1% of patients having resolution at day 28 compared with 28.9% of patients with no subretinal fluid at baseline.

The difference in rate and size of nonsurgical full thickness macular hole closures between groups at month 24 were not statistically significant.

No new safety signals were identified and adverse events resolved in the majority of cases within specific time periods.

In a substudy of expert-defined electroretinography (ERG) abnormalities, 92.5% of patients in the ocriplasmin group experienced no ERG changes or changes that resolved by the end of the study. Median time to resolution was 6 months. — by Kristie L. Kahl

Reference:

Kaiser PK. The OASIS study evaluating ocriplasmin for the treatment of symptomatic VMA/VMT, including macular hole over 2 years. Presented at: American Academy of Ophthalmology annual meeting. Nov. 14, 2015; Las Vegas.

Disclosure: Kaiser reports he is a consultant for Alcon, Novartis and Thrombogenics.